GRI Bio shareholders approve reverse stock split; company addresses Nasdaq equity deficiency with $8M offering

GRI Bio, Inc.

Shareholders approved reverse stock split at ratio between 1:2 and 1:30, with board discretion to set exact ratio or abandon.
Company received Nasdaq deficiency notice on Nov 26, 2025 for stockholders' equity below $2.5M.
Dec 12, 2025 public offering raised ~$8.0M gross proceeds, bringing equity above the $2.5M minimum.
Nasdaq will monitor compliance at next periodic report; failure may lead to delisting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.